Press releases
Novasep announces the success of its consent solicitation extending the maturity of its notes
• All resolutions were approved by 100% of the participating Noteholders and C Warrantholders
• Noteholders representing 99.9% of total outstanding principal amount participated
Enzene Biosciences chooses Novasep BioSC® Pilot chromatography for its automated end to end continuous manufacture of mAb.
Novasep, a leading supplier of services and technologies for the life sciences industry, announces Enzene Biosciences (India) has chosen BioSC® Pilot for purification of biopharmaceuticals to operate in its Pune plant.
Novasep announces the launch of a consent solicitation for the maturity extension of notes with requisite voting majority of the noteholders already secured
Novasep Holding S.A.S (“Novasep”), a leading supplier of services and technologies for the life sciences industry, announces the launch of a consent solicitation (the “Consent Solicitation”) in order to, inter alia:
Novasep industrializes potato protein purification unit for Solanic B.V.
This represents a step forward for the plant-based protein purification industry, with the first compact bed chromatography system for the purification of vegetable proteins.
Novasep opens €27m new Viral Vector Commercial Production Facility
With this new Viral Vector bioproduction facility, Novasep confirms its leadership position and effectively addresses the growing gene therapy market demand
Novasep Custom Manufacturing Site Passes Fifth Consecutive FDA Inspection Without 483s
Novasep’s robust quality assurance system, fully compliant with the highest world standards, showcased during successful FDA inspection of the Chasse-sur-Rhône (France) facility.
Novasep launches BioSC® Pilot, breakthrough chromatography and DSP skid for biologics purification
BioSC Pilot® is a new tool for continuous and intensified downstream processes in the biopharmaceutical industry.
Novasep invests €10M in “SeneFill”, its new facility for commercial aseptic Fill & Finish operations
This facility, located in Seneffe (Belgium), will strengthen Novasep’s drug product services for mAbs, viral vectors and other low volume biopharmaceuticals
Novasep announces 2017 financial results
Sales are up 4% at 282 M€
EBITDA is up 4.3% at 29 M€
Novasep supplies Complete Process Line to MEFSCO corn milling facility
The starch sweeteners plant will serve the growing Middle Eastern food and beverage market.